Dataset opportunity
Endoscout — 医疗影像数据集机会
Endoscout 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
40
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场将从 2025 年的 37.9 亿美元增长到 2030 年的 202.8 亿美元，复合年增长率为 39.9%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
中等
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Endoscout 持有一个大量医疗影像数据集，其中包含从其医疗设备收集的图像，并辅以业务记录、病历和监管文件。这一强大的集合专门用于训练和验证诊断人工智能算法，提供了丰富、可验证的真实临床证据来源。
全球医疗影像人工智能市场展示了该数据的巨大价值，预计将从 2025 年的 37.9 亿美元增长到 2030 年的 202.8 亿美元，复合年增长率高达 39.9%。[1] 尽管存在临床试验数据共享所有权和严格的 GDPR 限制等访问复杂性，但显著的增长凸显了对稀有、高质量数据集以支持下一代诊断工具的迫切需求。⚠ 尽职调查（有价值的数据，可协商访问）：临床试验数据涉及多中心医生发起的研究，可能存在共享所有权；物流和账单数据（endocare）涉及敏感的医院和保险交易记录；医疗设备性能数据受严格的 GDPR 和医疗监管限制。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Endoscout 拥有一个高价值的数据集，该数据集源自一项前瞻性的多中心临床试验，包含与特定患者结局相关的医疗影像。这些研究级数据，可能还包含账单和行政记录，正是医疗人工智能公司构建、测试和验证下一代诊断人工智能算法所必需的。在一个预计每年增长近 40% 的市场中，获得具有此类临床和真实世界背景的数据集将带来显著的竞争优势。
See dimension details ↓- Dataset Specificity78
占主导地位的“病历”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求异常高，这得益于医疗影像人工智能市场的指数级增长，该市场正以 39.9% 的复合年增长率扩张。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 种证据类型，4 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit33
⚠ 审查 — 该公司是医疗设备的经销商，于 2021 年被收购，其网站现推广用于息肉检测的 AI 软件；它似乎不持有作为运营业务副产品的专有数据。问题：公司的核心业务是销售第三方医疗设备，以及最近的 AI 软件，这属于明确的排除标准；该公司于 2021 年被西班牙 iVascular 集团收购，成为其子公司，而非独立的上市公司。[12]；网站 endoscout.de 现推广“EndoScout AI”，这是一款用于实时息肉检测的 AI 软件，属于“销售智能”范畴，不适合；原始业务是血管产品的分销，而不是产生专有数据作为副产品的业务。[4, 12]
- Deep Qualification80
✓ 通过 — Endoscout 是血管医疗设备的经销商，现为 iVascular 的一部分。它通过销售、服务和参与临床试验产生数据，但这些临床数据的所有权可能与试验发起者和医生共享，并且所有数据都受到严格的医疗保健法规的约束。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
持有者维护结构化的产品目录和技术信息，表明其有能力管理可将图像与特定医疗设备关联的元数据。
Medical records / imaging
这证实了存在一项前瞻性的多中心临床试验，证明了对与纵向临床结局相关联的研究级图像的所有权——这是训练诊断模型的黄金标准。
business_records
证据表明持有者管理全方位服务的账单和物流，这表明核心影像数据可以通过有价值的行政和索赔数据进行丰富，以获得更完整的患者视图。
Regulatory records
持有者展示了分析来自主要德国保险数据库的大规模真实世界数据的经验，这表明其在驾驭复杂的欧洲医疗保健数据领域方面拥有专业知识。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Endoscout Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market to grow from $3.79 billion in 2025 to $20.28 billion in 2030, at a CAGR of 39.9% (source: The Business Research Company). [1]. Investment score 40.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Nuday — 工业传感器数据集机会
View opportunity →其他Greenhousedatacenters — 传感器遥测数据集机会
View opportunity →mobilityFoodcareplus — 法规记录数据集机会
View opportunity →